MAJI — Exousia Pro Share Price
- $4.13m
- $4.37m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | n/a | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | n/a | ||
Price to Sales | n/a | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | n/a | ||
Return on Equity | n/a | ||
Operating Margin | n/a |
Financial Summary
Year End 30th Apr | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Exousia Pro, Inc., formerly Marijuana, Inc., is a clinical-stage biotechnology company, which is engaged in developing new ways to use the therapeutic potential of exosomes, initially focused on oncology. The Company's mammalian exosomal technology platform has shown the capability to increase the efficacy of Merck's drug Temozolomide (TMZ) in the treatment of glioblastoma (GBM). Its patented manufacturing process utilizes plant-based materials to create exosomes used in a number of commercial applications from dermatology to dentistry. The Company's proprietary loading technology can infuse a range of molecules from drugs to deoxyribonucleic acid (DNA).
Directors
- Last Annual
- April 30th, 2020
- Last Interim
- January 31st, 2021
- Incorporated
- August 4th, 2023
- Public Since
- December 28th, 2010
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Pink Sheets on Nasdaq
- Shares in Issue
- 35,094,567

- Address
- 7901 4Th Street N #23494, ST PETERSBURG, 33702
- Web
- https://exousiapro.com/
- Phone
- +1 5096056533
- Auditors
- Heaton & Company PLLC
Upcoming Events for MAJI
Similar to MAJI
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
As of Today at 21:53 UTC, shares in Exousia Pro are trading at $0.12. This share price information is delayed by 15 minutes.
Shares in Exousia Pro last closed at $0.12 and the price had moved by +6.91% over the past 365 days. In terms of relative price strength the Exousia Pro share price has underperformed the S&P500 Index by -5.7% over the past year.
There is no consensus recommendation for this security.
Find out moreExousia Pro does not currently pay a dividend.
Exousia Pro does not currently pay a dividend.
Exousia Pro does not currently pay a dividend.
To buy shares in Exousia Pro you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.12, shares in Exousia Pro had a market capitalisation of $4.13m.
Here are the trading details for Exousia Pro:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: MAJI
Based on an overall assessment of its quality, value and momentum Exousia Pro is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Exousia Pro. Over the past six months, its share price has outperformed the S&P500 Index by +115.58%.
As of the last closing price of $0.12, shares in Exousia Pro were trading +41.8% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Exousia Pro PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.12.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Exousia Pro's management team is headed by:
- Justin Costello - PRE
- David Cutler - CFO
- Donald Ross - DRC